Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval
Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared…
Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval
Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda. The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins…
For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS. The post For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients appeared first on MedCity News.
Leading Quality Care When The Odds Are Stacked Against You
Leading in healthcare when the odds are stacked against you is not about eliminating the challenges. It is about meeting them without losing sight of the reason we chose this profession in the first place. The post Leading Quality Care When The Odds Are Stacked Against You appeared first on MedCity News.
Leading Quality Care When The Odds Are Stacked Against You
Leading in healthcare when the odds are stacked against you is not about eliminating the challenges. It is about meeting them without losing sight of the reason we chose this profession in the first place. The post Leading Quality Care When The Odds Are Stacked Against You appeared first on MedCity News.
Journalists Follow the Fallout of CDC Director’s Firing and Trump’s Health Policies
KFF Health News chief Washington correspondent Julie Rovner discussed the Senate hearing of former Centers for Disease Control and Prevention director Susan Monarez on WBUR’s “Here & Now” on Sept. 17. Rovner also delved into the “Make America Healthy Again” report on children’s health on WNYC’s “The Brian Lehrer Show” on Sept. 16 and on…
Inequality aversion and option value
Many policymakers aim to reduce health disparities across groups. In fact, the distributional cost effectiveness analysis (DCEA) approach aims to incorporate treatment value based on the extent to which they reduce inequality. However, what types of inequality are we trying to reduce: ex-post or ex-ante? Ex post inequality means reducing inequality of outcomes at a…
Mercury in Your Hot Dog? Vaccine Skeptics Face Their Limits at Crucial CDC Meeting
ATLANTA — Public health officials watched with dread as a panel shaped by the Trump administration took up an agenda to begin dismantling six decades of vaccination development and progress. But while the result seemed foretold, the debate was far from unanimous. The Advisory Committee on Immunization Practices, or ACIP, met at a satellite campus…
What’s Top of Mind for 3 Healthcare Execs on Deploying AI
During the MedCity INVEST Digital Health conference in Dallas, three executives shared what’s top of mind as they deploy AI in the healthcare workforce, including the need to build trust and improve interoperability. The post What’s Top of Mind for 3 Healthcare Execs on Deploying AI appeared first on MedCity News.
Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says
At MedCity News’ INVEST Digital Health conference, Sanford Health’s virtual care chief Dave Newman pointed out that in rural America, virtual care often determines whether patients receive treatment at all. He described how Sanford has expanded beyond video visits to include various other modalities like e-visit questionnaires, remote monitoring and even phone consults — saving…
Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease
Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup. The post Two Is Better Than One: Startup Dualitas Lands $65M to…
